Treace Medical Concepts (NASDAQ:TMCI) Upgraded to Sell at Wall Street Zen

Key Points

• Wall Street Zen upgraded Treace Medical Concepts from "strong sell" to "sell," but the stock still has a consensus rating of "Reduce" with a consensus target price of $4.77.
• Shares opened at $1.98 (12‑month range $1.17–$7.78) and the company shows a negative P/E (-2.11); last quarter EPS was -$0.15 (in line with estimates) while revenue of $62.52M slightly beat expectations.
• Institutional investors own about 84.08% of the company, with recent large moves including CIBC Bancorp USA buying a new position (~$122.2M) and multiple firms materially increasing stakes.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "strong sell" rating to a "sell" rating in a research report issued to clients and investors on Monday.

A number of other equities research analysts also recently issued reports on the company. Lake Street Capital decreased their price objective on Treace Medical Concepts from $7.50 to $7.00 and set a "buy" rating on the stock in a research report on Monday, March 2nd. Stifel Nicolaus decreased their price objective on Treace Medical Concepts from $5.00 to $3.00 and set a "hold" rating on the stock in a research report on Wednesday, January 7th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Treace Medical Concepts in a research report on Monday, April 20th. One analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Reduce" and a consensus target price of $4.77.

Treace Medical Concepts Price Performance

NASDAQ:TMCI opened at $1.98 on Monday. The company has a current ratio of 4.31, a quick ratio of 3.13 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $128.26 million, a P/E ratio of -2.11 and a beta of 0.87. Treace Medical Concepts has a 12 month low of $1.17 and a 12 month high of $7.78. The business's 50-day moving average is $1.63 and its 200 day moving average is $2.86.

Treace Medical Concepts (NASDAQ:TMCI - Get Free Report) last posted its earnings results on Friday, February 27th. The company reported ($0.15) EPS for the quarter, hitting analysts' consensus estimates of ($0.15). Treace Medical Concepts had a negative return on equity of 59.91% and a negative net margin of 27.74%.The company had revenue of $62.52 million for the quarter, compared to the consensus estimate of $61.76 million. On average, equities research analysts forecast that Treace Medical Concepts will post -0.92 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. CIBC Bancorp USA Inc. bought a new position in Treace Medical Concepts in the third quarter worth approximately $122,199,000. Gagnon Securities LLC grew its stake in Treace Medical Concepts by 37.7% in the fourth quarter. Gagnon Securities LLC now owns 3,110,575 shares of the company's stock worth $7,621,000 after purchasing an additional 852,337 shares in the last quarter. Weber Capital Management LLC ADV bought a new position in Treace Medical Concepts in the fourth quarter worth approximately $1,445,000. Gagnon Advisors LLC grew its stake in Treace Medical Concepts by 58.4% in the fourth quarter. Gagnon Advisors LLC now owns 1,534,034 shares of the company's stock worth $3,758,000 after purchasing an additional 565,570 shares in the last quarter. Finally, William Blair Investment Management LLC grew its stake in Treace Medical Concepts by 17.2% in the third quarter. William Blair Investment Management LLC now owns 3,634,381 shares of the company's stock worth $24,387,000 after purchasing an additional 534,486 shares in the last quarter. Institutional investors own 84.08% of the company's stock.

Treace Medical Concepts Company Profile

Treace Medical Concepts, Inc is a medical technology company specializing in the development and commercialization of innovative surgical solutions for foot and ankle conditions. The company's flagship product, the Lapiplasty 3D Bunion Correction System, addresses the underlying joint instability that causes bunion deformity through a patented, multi-plane correction approach. The system combines proprietary instrumentation, fixation plates, and a comprehensive surgical protocol designed to improve patient outcomes and reduce recurrence rates.

The Lapiplasty System has received clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.